NASDAQ:MNKD MannKind Q3 2026 Earnings Date & Estimates $3.04 -0.09 (-2.72%) As of 02:31 PM Eastern This is a fair market value price provided by Massive. Learn more. MannKind is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 9:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeAfter Market ClosesConference Call9:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from MannKind in Q3 2026MannKind is expected to post earnings of -$0.0575 per share on revenue of $109.50 million. In the same quarter a year earlier MannKind reported $0.03 per share on revenue of $82.13 million. MannKind last reported on August 5, 2026, posting -$0.01 per share and missing the -$0.0075 consensus estimate. MannKind has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.0575Expected Revenue$109.50 millionPrior-Year EPS$0.03Prior-Year Revenue$82.13 millionExpected EPS Growth-291.7%Expected Revenue Growth+33.3%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.01 (Missed by -$0.0025)Last Quarter Revenue$109.37 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report MannKind Q3 2026 Earnings FAQ When does MannKind report Q3 2026 earnings? MannKind (NASDAQ:MNKD) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is MannKind's Q3 2026 earnings call? MannKind's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 9:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for MannKind? Analysts expect MannKind to post earnings of -$0.0575 per share for Q3 2026. How much revenue is MannKind expected to report? The consensus revenue estimate for MannKind is $109.50 million for Q3 2026. MannKind Earnings HeadlinesMannKind Corporation (NASDAQ:MNKD) Stock Has Average Target Price of $7.84 According to BrokeragesOctober 12 at 2:29 AM | americanbankingnews.comTruist Financial Keeps Their Buy Rating on MannKind (MNKD)October 10 at 5:44 PM | theglobeandmail.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 13 at 1:00 AM | The Oxford Club (Ad)Mannkind Corporation Presents New Clinical Data Related to Furoscix Readyflow At Heart Failure Society of America Annual Scientific MeetingOctober 10 at 7:38 AM | marketscreener.comMMannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)October 9, 2026 | globenewswire.comMannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026October 9, 2026 | quiverquant.comQSee More MannKind Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MannKind? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MannKind and other key companies, straight to your email. Email Address About MannKindMannKind (NASDAQ:MNKD) (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life. Learn more at mannkindcorp.com.View MannKind ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09 Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
